News
Novo Nordisk CFO Karsten Munk Knudsen tells Yahoo Finance the company understands the pressure it is under to deliver better ...
The company hopes an important CVS deal and broader legal action against the makers of knockoff Wegovy can solidify its slipping position in the lucrative market for weight loss drugs.
Novo claims the defendants are steering patients toward compounded semaglutide that has not been approved by regulators; in ...
The pharmaceutical company's quarterly sales of its blockbuster Wegovy drug surged by two-thirds, despite many Americans ...
Novo Nordisk ( NVO -4.02%) stock imitated the company's leading product on Wednesday by slimming down in price. The Danish pharmaceutical's shares lost nearly 4% of their value following its latest ...
Novo Nordisk experiences heightened competition from copycat versions of its Wegovy obesity drug, affecting its market share, ...
Shares in Novo Nordisk fell as much as 6% on Friday before recovering some ground later in the session, extending recent ...
Noom introduces affordable options for obesity treatments, including Novo Nordisk's Wegovy and GLP-1Rx programs. Read more ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback